Loxo Oncology Inc

Loxo Oncology — Corporate Update (December 2016)

42 slides from Loxo Oncology's corporate update, Dec 19, 2016

  1. Slide 1: Forward Looking Statements

    Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anti

  2. Slide 2: Agenda for Today's Call

    Agenda for Today’s Call Introduction Review updated larotrectinib (LOXO-101) adult Phase 1 data presented at ESMO Asia Outline larotrectinib development timelines and commercial opportunity LOXO-195 overview and program rationale LOXO-292 overview and program rationale Guidance on corporate mileston

  3. Slide 3: Loxo Oncology: Foundational Theses

    Loxo Oncology: Foundational Theses Targeted therapies remain an essential category for new drug development in oncology Address low mutational burden/ IO-refractory, oncogene addicted cancers Leverage clinical and pathology trends towards comprehensive tumor profiling Potency, specificity and well-b

  4. Slide 4: A Space in Evolution: Accidental Kinase Inhibitors Yield to Purpose-Built Drugs

    A Space in Evolution: “Accidental” Kinase Inhibitors Yield to Purpose-Built Drugs 5 Historical Approach Modern Approach CEP-701 / lestaurtinib TRK LOXO-101 / larotrectinib LOXO-292 CEP-32496 / RXDX-105 RXDX-101 / entrectinib Ibrance® / palbociclib Jakafi® / ruxolitinib Iclusig® / ponatinib

  5. Slide 5: Loxo Oncology: History of Focused Execution

    Loxo Oncology: History of Focused Execution 6 2013 Company founded 2014 LOXO-101 IND filed Initial public offering 2015 First TRK fusion patient enrolled First data reported in patients with TRK fusion cancers Initiated NAVIGATE Phase 2 study Initiated SCOUT pediatric Phase 1/2 study 2016 LOXO-101 b

  6. Slide 6: Loxo Oncology: History of Focused Execution

    Loxo Oncology: History of Focused Execution @.: ) 2016 Potentially submit oo ia LOXO-101 NDA © breakthrough LOXO-195 IND 2015 py LOXO-292 IND thera First TRK fusion designation patient enrolled cry ESMO Asia ( } 2014 First data reported Phase 1 durability in patients with updates Beye tOL IND TRK fu

  7. Slide 7: Larotrectinib: Ongoing Clinical Trials

    Larotrectinib: Ongoing Clinical Trials Adult Phase 1 Data disclosed at EORTC 2015, AACR 2016, and ESMO Asia 2016 N=7 TRK fusion patients evaluable as of ESMO Asia 2016 presentation Enrollment ongoing Pediatric Phase 1/2 (SCOUT) First patient enrolled published as a case report in Spring 2016 Enrollm

  8. Slide 8: Best Response to Larotrectinib and Duration of Therapy for Patients with TRK Fusions

    Best Response to Larotrectinib and Duration of Therapy for Patients with TRK Fusions 9 Data shown from Phase 1 trial, as presented at ESMO Asia 2016 by Dr. Todd Bauer Data cutoff November 10, 2016. * PR=partial response. Response is based on the investigator’s assessment using RECIST 1.1. Duration o

  9. Slide 9: Larotrectinib Well-Positioned for Infantile Fibrosarcoma (IFS)

    Larotrectinib Well-Positioned for Infantile Fibrosarcoma (IFS) IFS presents unique opportunity for LOXO-101 Different commercially-facing product (i.e. liquid) Clinical impact may be very high (i.e. limb salvage) Market opportunity Estimated ~100 cases/year in the US1 Tumor type identified by histol

  10. Slide 10: Larotrectinib: Emerging Regulatory Clarity

    Larotrectinib: Emerging Regulatory Clarity Breakthrough therapy designation (BTD) granted in July 2016 BTD indication: “For the treatment of unresectable or metastatic solid tumors with NTRK-fusion proteins in adult and pediatric patients who require systemic therapy and who have either progressed f

  11. Slide 11: Larotrectinib: Emerging Regulatory Clarity

    Larotrectinib: Emerging Regulatory Clarity Breakthrough therapy designation (BTD) granted in July 2016 BTD indication: “For the treatment of unresectable or metastatic solid tumors with NTRK-fusion proteins in adult and pediatric patients who require systemic therapy and who have either progressed f

  12. Slide 12: Larotrectinib Regulatory Feedback

    Larotrectinib Regulatory Feedback Trial design and endpoints Ongoing Phase 2 NAVIGATE trial will form the basis of an NDA Primary endpoint: RECIST v1.1 overall response rate (ORR) based on independent radiology review Durability and safety will be key components of the risk-benefit determination upo

  13. Slide 13: Larotrectinib Enrollment Update

    Larotrectinib Enrollment Update Currently ~85% enrolled to goal for primary efficacy analysis population of NDA submission Expect full enrollment early 2017 Enrolling worldwide US, EU, S Korea, Singapore, Japan Streamlined site selection Dozens of patients with TRK fusions enrolled across >10 differ

  14. Slide 14: Standard NDA/MAA Elements

    Standard NDA/MAA Elements Clinical Last patient in Patient follow-up Independent radiology review Clinical study report CMC scale-up and stability testing Dictates the expiration date of the commercial product Long-term toxicology Clinical pharmacology studies Drug-drug interactions Food effect ADME

  15. Slide 15: Larotrectinib in Perspective: Precedent Oncology Drug Timelines

    Larotrectinib in Perspective Precedent Oncology Drug Timelines Years from IND to NDA Afatinib 9.0 Alemtuzumab 8.1 Axitinib 9.6 Belinostat 9.2 Bevacizumab 6.2 Bortezomib 4.5 Bosutinib 7.6 Brentuximab vedotin 4.7 Cabozantinib 7.0 Carfilzomib 6.4 Ceritinib 3.3 Cetuximab 9.0 Crizotinib 5.3 Dabrafenib 3.

  16. Slide 16: Larotrectinib in Perspective: Precedent Oncology Drug Timelines

    Larotrectinib in Perspective Precedent Oncology Drug Timelines Years from IND to NDA Afatinib 9.0 Alemtuzumab 8.1 Axitinib 9.6 Belinostat 9.2 Bevacizumab 6.2 Bortezomib 4.5 Bosutinib 7.6 Brentuximab vedotin 4.7 Cabozantinib 7.0 Carfilzomib 6.4 Ceritinib 3.3 Cetuximab 9.0 Crizotinib 5.3 Dabrafenib 3.

  17. Slide 17: Larotrectinib: Commercial Opportunity

    Larotrectinib: Commercial Opportunity Loxo Oncology has commissioned proprietary work to better understand the frequency of TRK+ cancers i.e. tumor banks and third party lab relationships Proprietary datasets suggest 1,500-5,000 late-line eligible patients per year in US Similar estimates for EU5 an

  18. Slide 18: Crizotinib for ALK: A Diagnostics Case Study

    Crizotinib for ALK: A Diagnostics Case Study August 2011: Initial FDA approval with Abbott FISH diagnostic June 2015: FDA approval of Ventana IHC diagnostic November 2016: Submission of PMA for Thermo Fisher Oncomine Universal Dx Test (NGS) 19 FISH = Fluorescent in situ hybridization IHC = Immunohis

  19. Slide 19: ALK+ NSCLC: A Commercial Case Study

    ALK+ NSCLC: A Commercial Case Study 20 Source: Pfizer, Novartis, and Roche financial reports. Xalkori, Zykadia, and Alecensa package inserts. Note: Market potential for larotrectinib may differ from that indicated by historical revenues for ALK+ NSCLC. * Xalkori was also FDA-approved for ROS1+ NSCLC

  20. Slide 20: ALK+ NSCLC: A Commercial Case Study

    ALK+ NSCLC: A Commercial Case Study $700 ine haere tsornndiocteee eeu us $600 : 00 late-line haere tsornndiocteee eeu inus = $500 8 s00 ." % $300 z 3 5 $200 $100 Ea o— 2011 = 2012, 2013S 2014 = 2015-2016 YTD, om* Ae zvKania mb cae US XALKORI al Median curation of 74113 7474 75112 ‘Source: Pfizer, No

  21. Slide 21: Mutations that limit drug binding are the most common form of acquired resistance

    Mutations that limit drug binding are the most common form of acquired resistance; often the oncogene-addicted tumor remains addicted to the same oncogene Early lines of evidence offer a molecular understanding of potential mechanisms of resistance to larotrectinib in TRK fusion patients: Preclinica

  22. Slide 22: LOXO-195: Development Opportunity Foreshadowed by Other Classes

    LOXO-195: Development Opportunity Foreshadowed by Other Classes Clinically, addressing acquired resistance allows clinicians and patients to maximize total duration of disease control over multiple lines of therapy ALK+ NSCLC Primary response on crizotinib 30-50% develop various mutations conferring

  23. Slide 23: LOXO-195: Selectivity

    LOXO-195: Selectivity 24 LOXO-195 LOXO-101 Entrectinib TRKB TRKB TRKA TRKB TRKA TRKA Blake et al. EORTC-NCI-AACR 2016. Abstract 442. Kinase LOXO-195 % control TRKA 0.5 TRKB 0 EGFR 100 KIT 100 Met 100 PDGFRalpha 100 PDGFRbeta 100 KDR (VEGFR2) 100

  24. Slide 24: LOXO-195: Potency Against Diverse Resistance Mutations

    LOXO-195: Potency Against Diverse Resistance Mutations 25 Blake et al. EORTC-NCI-AACR 2016. Abstract 442. D TRKA 0.01 0.1 1 10 100 1000 10000 0 25 50 75 100 Drug Concentration (nM) p T R K ( % o f C o n t r o l ) ETV6-NTRK3 0.01 0.1 1 10 100 1000 10000 0 25 50 75 100 Drug Concentration (nM) p E R K

  25. Slide 25: LOXO-195: In Vivo Tumor Regressions

    LOXO-195: In Vivo Tumor Regressions 26 Blake et al. EORTC-NCI-AACR 2016. Abstract 442. Vehicle 30 mg/kg BID LOXO-195 100 mg/kg BID LOXO-195 300 mg/kg BID LOXO-195 60 mg/kg QD LOXO-101 Vehicle 30 mg/kg BID LOXO-195 100 mg/kg BID LOXO-195 300 mg/kg BID LOXO-195 60 mg/kg QD LOXO-101 0 2 4 6 8 10 12 0 1

  26. Slide 26: LOXO-195

    LOXO-195 LOXO-195 preclinically active against all acquired resistance mutations identified to date LOXO-195 Phase 1 study expected to start by mid-2017 Operational synergy with larotrectinib program Expect single agent activity at biologically relevant doses Assuming availability of appropriate pat

  27. Slide 27: LOXO-195

    LOXO-195 + LOXO-195 preclinically active against all acquired resistance mutations identified to date + LOXO-195 Phase 1 study expected to start by mid-2017 — Operational synergy with larotrectinib program — Expect single agent activity at biologically relevant doses + Assuming availability of appro

  28. Slide 28: RET (REarranged during Transfection)

    RET (REarranged during Transfection) Adapted from Mulligan, Nature Reviews Cancer (2014) 14: 173-185; Besset, JBC 2000 275: 39159-39166 Wild-type RET Extracellular mutation C634R Intracellular mutation M918T Oncogenic fusion KIF5B-RET CCDC6-RET ~60% medullary thyroid cancer ~2% NSCLC, 10-20% papilla

  29. Slide 29: M918T Clinically Validated in MTC

    M918T Clinically Validated in MTC EXAM Phase 3 Trial, cabozantinib vs. pbo Source: Schlumberger, ASCO 2015 ITT Population HR 0.15 p<0.0001 HR 0.67 p=0.1875 30

  30. Slide 30: Multikinase Inhibitors Have Clinically Validated RET Fusions in NSCLC

    Multikinase Inhibitors Have Clinically Validated RET Fusions in NSCLC 31 Drug Publication N RECIST ORR1 Median PFS Issues Cabozantinib Initial data: ASCO 2015 Follow-up data: Lancet Oncol 2016 16 25 38% (6/16) 28% (7/25) 7m 5.5m Frequent AEs and dose reductions Lenvatinib ESMO 2016 25 16% (4/25) 7.3

  31. Slide 31: Multikinase Liabilities On Display

    Multikinase Liabilities On Display 32 Excerpt from commentary “ ”

  32. Slide 32: RET: Incomplete Target Coverage with Multikinase Inhibitors

    hERG IC50 100 10 1 0.1 0.01 Vandetanib 300mg QD RET IC50 RET IC90 KDR IC50 EGFR IC90 EGFR IC50 KDR IC90 100 10 1 0.1 0.01 RET IC50 hERG IC50 MET IC50 RET IC90 KDR IC50 MET IC90 KDR IC90 Cabozantinib 140 mg QD 60 mg QD RET: Incomplete Target Coverage with Multikinase Inhibitors Human exposure (plasma

  33. Slide 33: RET: Product Profile Goals

    RET: Product Profile Goals Potent against RET fusions and mutations Superior RET inhibition in pharmacodynamic models Tumor regression in in vivo models Activity against predicted acquired resistance mutations, such as V804M and V804L Avoid off-targets such as VEGFR, Aurora kinase, FGFR, EGFR, MET E

  34. Slide 34: LOXO-292: KDR/VEGFR2 Selectivity

    LOXO-292: KDR/VEGFR2 Selectivity 35 Vandetanib LOXO-292 1:10 1:100 1:1 RET:KDR 10 10 100 4000 100 40 40 4 1 RET cell IC50 (nM) 400 1000 1000 400 KDR/VEGFR2 cell IC50 (nM) Cabozantinib Vandetanib LOXO-292 Brandhuber et al. EORTC-NCI-AACR 2016. Abstract 441.

  35. Slide 35: LOXO-292: Log-Scale Cell Line Selectivity

    LOXO-292: Log-Scale Cell Line Selectivity 36 No RET alteration (n=83) RET alteration (n=4) Insensitive Sensitive Cabozantinib Vandetanib LOXO-292 10 100 1000 Cell Count EC50 (nM) Brandhuber et al. EORTC-NCI-AACR 2016. Abstract 441.

  36. Slide 36: LOXO-292: Anticipating Resistance

    LOXO-292: Anticipating Resistance 37 Brandhuber et al. EORTC-NCI-AACR 2016. Abstract 441. RET Mutation WT V804M V804L A883F M918T S891A KIF5B-RET/RET M918T 0.01 0.1 1 10 100 1000 10000 0 25 50 75 100 Drug Concentration (nM) p R E T ( % o f C o n t r o l ) LOXO-292 KIF5B-RET Cabozantinib KIF5B-RET Va

  37. Slide 37: LOXO-292: In Vivo Tumor Regressions

    LOXO-292: In Vivo Tumor Regressions 38 Brandhuber et al. EORTC-NCI-AACR 2016. Abstract 441. 0 5 10 15 0 200 400 600 800 1000 NIH 3T3 KIF5B-RET Day T u m o r V o l u m e ( m e a n ± S E M , m m 3 ) 0 5 10 15 0 500 1000 1500 2000 2500 NIH 3T3 KIF5B-RET V804M Day T u m o r V o l u m e ( m e a n ± S E M

  38. Slide 38: LOXO-292 Clinical Development

    LOXO-292 Clinical Development LOXO-292 Phase 1 study expected to start in early 2017 Opportunity for patient enrichment in Phase 1 Growing target awareness Detection technology is relatively straightforward Expect single agent activity at biologically relevant doses Potential for initial clinical da

  39. Slide 39: LOXO-292 Clinical Development

    LOXO-292 Clinical Development LOXO-292 Phase 1 study expected to start in early 2017 * Opportunity for patient enrichment in Phase 1 — Growing target awareness — Detection technology is relatively straightforward + Expect single agent activity at biologically relevant doses + Potential for initial c

  40. Slide 40: Milestones and Capitalization

    Milestones and Capitalization 41 PROGRAM UPDATE ESTIMATED TIMEFRAME Larotrectinib (LOXO-101, TRK) Complete enrollment for primary efficacy analysis dataset Early 2017 Present Phase 1/2 pediatric clinical data Mid-2017 Announce top-line data for NDA dataset 2H 2017 Submit NDA with US FDA Late 2017 /

  41. Slide 41: Loxo Oncology: History of Focused Execution

    Loxo Oncology: History of Focused Execution 42 Cash runway through larotrectinib NDA submission and potential approval 2013 Company founded 2014 LOXO-101 IND filed Initial public offering 2015 First TRK fusion patient enrolled First data reported in patients with TRK fusion cancers Initiated NAVIGAT

  42. Slide 42: Loxo Oncology: History of Focused Execution

    Loxo Oncology: History of Focused Execution Cash runway through larotrectinib NDA submission and potential approval @:. r ) 2016 Potentially submit Tose LOXO-101 NDA @ breakthrough LOXO-195 IND 2015 theray LOXO-292 IND Py First TRK fusion designation patient enrolled ‘AACR/ ESMO Asia e First data re

Loxo Oncology — Corporate Update (December 2016) on 6ix